AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06188676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF
Study NCT06188676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEG-filgrastim
Study NCT06188676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: PEG-filgrastim
Study NCT06188676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: Opdivo
Study NCT05712837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% TRICHLOROACETIC ACID
Description: Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
Study NCT05712837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% salicylic acid
Description: Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
Study NCT05868278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training method intervention
Description: Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
Study NCT05825300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email message
Description: Email message encourages patients to donate blood
Study NCT05825300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social responsibility
Description: Message specifies that there is a shortage of the patient's blood type
Study NCT06337227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA signature analyses
Description: Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
Study NCT04728139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: glypican 3
Description: Assessment of glypican 3 presence in colorectal cancer patients using ELISA
Study NCT05284955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
Study NCT05284955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heart failure medical therapy
Description: Standard heart failure medical therapy as recommended by guidelines.
Study NCT05888610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Outpost
Description: A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
Study NCT04996940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette product
Description: Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette
Study NCT05732805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
Study NCT05732805 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCD-100
Description: Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
Study NCT05732805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
Study NCT05732805 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05732805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05338697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
Study NCT05536206 — intervention group
Intervention type: DEVICE
Intervention: Wireless and continuously monitoring
Description: Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
Study NCT05355129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00920
Description: Tablets
Study NCT05355129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-00920 Placebo
Description: Tablets
Study NCT04814602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proglumide
Description: CCK receptor antagonist
Study NCT04814602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proglumide
Description: CCK receptor antagonist
Study NCT05733676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
Study NCT05733676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride
Description: Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
Study NCT06156059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bedtime Melatonin
Description: 100 mg oral suspension or capsule given at bedtime
Study NCT06156059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension or capsule
Description: Indistinguishable suspension or capsule
Study NCT05286463 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bee venom gel phonophoresis
Description: a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
Study NCT05286463 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low intensity ultrasound
Description: a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered Post-Transplant
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day +5
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
Study NCT05736419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: The dose and schedule of ATG will be determined according to the nomogram in Appendix A
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
Study NCT05736419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab on days -71, -58, -43, and -30.
Study NCT05068921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Study NCT05815615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies
Study NCT05815615 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies
Study NCT02376647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving pressure limited ventilation
Description: Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment.
Study NCT02376647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
Study NCT05638737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831
Study NCT05638737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04800939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with HT7 points and continue with SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
Study NCT04800939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Plasebo acupressure
Description: In the control group, the application will start with the points 1.5 cm around the HT7 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study NCT05996367 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-dose involved-site radiotherapy
Description: Single-dose of 8 Gy at involved-site radiotherapy
Study NCT05099289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor EV-ICD Lead
Description: Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
Study NCT04349007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard meal
Description: local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
Study NCT04349007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: School food ready-to-use
Description: 80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
Study NCT04349007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: School food ready-to-use plus Milk
Description: 80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
Study NCT05519553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: : 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
Study NCT05019170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based Financial Incentives
Description: Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
Study NCT05019170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
Study NCT05019170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
Study NCT05302440 — intervention group
Intervention type: DEVICE
Intervention: remote real-time health monitoring system with ring-like sensor
Description: The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
Study NCT05294965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoterol
Description: Intravenous infusion
Study NCT05294965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild cold exposure
Description: Body surface cooling
Study NCT04697953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brolucizumab
Description: Pre-filled Syringes for intravitreal injection
Study NCT05728697 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic ultrasound shear wave elastography
Description: To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
Study NCT04731259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-04
Description: ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
Study NCT04731259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05688618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteroccocus Facieum and Agave Inulin
Description: A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
Study NCT05688618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pack of unsweetened almond powder milk will be administered daily for 8 weeks
Study NCT05111405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CMC Arthroplasty
Description: Surgical intervention to treat CMC arthritis
Study NCT05280197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
Study NCT05280197 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: Transversus abdominis plane (TAP) nerve block with normal saline
Study NCT05280197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine plus free bupivacaine
Description: TAP block using liposomal bupivacaine plus free bupivacaine
Study NCT05280197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: TAP block using normal saline
Study NCT04751682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Vaccine
Description: Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.
Study NCT04751682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06474065 — intervention group
Intervention type: PROCEDURE
Intervention: Myomectomy
Description: Patients submitted to operation of fibroids removal
Study NCT05352945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyPNOS self-hypnosis mask from DREAMINZZ
Description: The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections
Study NCT03851081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT03851081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03851081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT06463236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guiding treatment
Description: Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
Study NCT06463236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: empirical therapy
Description: Experiential treatment by grassroots doctors
Study NCT04737837 — intervention group
Intervention type: DRUG
Intervention: lacosamide
Description: lacosamide as first add on therapy
Study NCT05036954 — intervention group
Intervention type: DEVICE
Intervention: EyeBrid Excel hybrid lenses
Description: new lenses
Study NCT06274242 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Haruna
Description: Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
Study NCT06274242 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Isolate Soy Protein and Isomalt
Study NCT05147337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.
Study NCT05761119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
Study NCT04360473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.